Envista Holdings Corp (NVST) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Envista Holdings Corp stock $6.45, price $25.17, that is 74.4% below the price, quality 69 out of 100. Rating: strongly overvalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range $14.76 – $50.90 · fair‑value band $4.87 – $8.06 · the $25.17 price screens above the $6.45 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Envista Holdings in your weekly email
Every Wednesday you see whether Envista Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables.
Show moreShow less
The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products.
This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands.
The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products.
This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
Stock analysis
Envista Holdings Corp (NVST) currently trades at $25.17, while our model-based Fair Value estimate is $6.45, 74% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $17.73 per share, and 1 of the 22 models we run sit above the $25.17 price.
Bear case: the Earnings-Based group reads lowest at $4.55, and 21 of the 22 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $4.87 (bear) to $8.06 (bull), the price of $25.17 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Envista Holdings Corp reported revenue of $2.7B in FY2025 versus $2.5B in FY2021, a compound +2.0%/yr. Reported net income was $47.0M in FY2025, compounding −39.0%/yr from FY2021.
Key figures
Market cap $4.1B Mid · P/E ratio 6.5 · P/S ratio 1.44 · EPS (TTM) $3.88 · Net margin 22.0% · Return on equity 20.5% · Return on assets (EBIT) −1.1% (5-year average) · Operating margin 11.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 59 out of 100 (low confidence).
What moves the price
Analysts expect earnings well below the last reported figure (earnings in transition, for example expiring patents or contracts); a fair value that looks fair on trailing earnings may then be too optimistic.
The share trades about 17% below its 52-week high and 33% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −74%, NVST screens richer than that median.
Fair Value models
Bear$4.87Fair Value $6.45Bull$8.06
Price $25.17 · Downside -74.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($3.33 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, one officer or director sold shares worth $220,000 and none bought.
SaleMischa ReisSVP, Strategy & Bus. Dev.2× since Feb 10, 2026: 17,675 shares, avg. $28.87$510,250Aug 20, 202610b5-1 plan
Plus 14 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.84/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+8.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
Start year 2020 (pandemic). Over 10 years: −0.1% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.1%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−29.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−29.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−29.5% vs −16.9%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 8%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 2.4%/yr over ~7Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +6.2% a year for the price and +1.4% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: Envista's main strength lies in advancing digital workflow and guided surgery platforms via Nobel Biocare to support premium dental implants, while its main weakness remains low net margins and ROE pointing to limited durable advantage.
Main risk: Volume-based procurement changes in China represent the biggest risk by introducing sustained pricing pressure on core dental products and directly compressing margins.
Envista continues to invest in digital workflow and guided surgery platforms through its Nobel Biocare portfolio to meet growing demand for implants. These moves aim to strengthen its position in premium dental solutions amid broader industry shifts. At the same time, volume-based procurement changes in China introduce pricing pressures on key products. Will the digital initiatives generate enough new revenue streams to offset those regional headwinds?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside−74.4% · Bottom 25%
Profitability
Return on equity (12 months)20.5% · Top 25%
Return on assets0.8% · Bottom 25%
Net margin (12 months)22.0% · Top 25%
Operating margin (12 months)11.4% · Below median
Growth and dividend
Revenue growth (quarter YoY)3.2% · Below median
Balance sheet
Debt / equity0.47× · Highest 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (12 months)6.5× · Cheapest 25%
P/B1.33× · Cheaper than median
P/S (12 months)1.44× · Cheaper than median
Price / free cash flow (fiscal year)17.9× · Cheaper than median
EV/EBITDA10.5× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 25
FUTURE (revenue growth)16· sector 40
PAST (return on equity)82· sector 30
HEALTH (low debt)77· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Envista Holdings Corp (NVST) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $6.45 versus a price of $25.17, about 74% lower (overvalued).
What is the fair value of NVST?
Our model-based fair value for Envista Holdings Corp is $6.45 (as of Nov 7, 2026), built from audited fundamentals. The current price: $25.17.
What is the quality score of NVST?
Envista Holdings Corp has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Envista Holdings Corp (NVST)?
Our model-based price target is the fair value of $6.45 (as of Nov 7, 2026) from 22 valuation models. Cautious scenario $4.87, optimistic scenario $8.06. It is a calculation from audited fundamentals, not an analyst target.
What is the Envista Holdings Corp stock forecast for 2026?
Our models put fair value at $6.45, about 74% lower versus a price of $25.17 (overvalued). Cautious scenario $4.87, optimistic scenario $8.06. The calculation is refreshed regularly with new filings.
What is the revenue of Envista Holdings Corp (NVST)?
Envista Holdings Corp reported trailing-twelve-month revenue of about $2.9B (latest available figure, as of Nov 7, 2026).
What growth is priced into Envista Holdings Corp (NVST)?
For today's price to be fair in a discounted-cash-flow model, Envista Holdings Corp would have to grow free cash flow by +8.7 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.1 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of NVST use?
Our models discount Envista Holdings Corp at 9.6 %: a base by market capitalisation (mid), damped by beta 0.94, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Envista Holdings Corp that is +8.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.6 %) and the same formula as our fair value.
How much growth has Envista Holdings Corp (NVST) delivered so far?
Over the past 5 years revenue at Envista Holdings Corp grew +7.1 % a year. The price currently implies free-cash-flow growth of +8.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Envista Holdings Corp (NVST) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Envista Holdings Corp (+8.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Envista Holdings Corp (NVST)?
The free-cash-flow yield on the price is 5.58 %: that much free cash flow Envista Holdings Corp produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Envista Holdings Corp (NVST)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Envista Holdings Corp it is $6.45 per share (as of Nov 7, 2026), against a price of $25.17. It is the blended result of 22 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Envista Holdings Corp stock overvalued or undervalued in 2026?
As of Nov 7, 2026, NVST trades above its calculated fair value: price $25.17, fair value $6.45, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NVST?
No. The price is what the market pays today ($25.17); the fair value is what the company's own numbers justify ($6.45). For Envista Holdings Corp the two are $18.72 per share apart. That gap is exactly why we show both numbers side by side.
How much is Envista Holdings Corp worth?
The market values Envista Holdings Corp at about $4.1B (market capitalisation, as of Nov 7, 2026). Per share that is $25.17; our models calculate a fair value of $6.45 per share.
What do the bullish and bearish scenarios say about NVST?
Our models span a range for Envista Holdings Corp: cautious scenario $4.87, base $6.45, optimistic $8.06 per share (as of Nov 7, 2026, price $25.17). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NVST?
Envista Holdings Corp trades at a price-to-earnings ratio of 6.5 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $6.45 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2019 to 2025), reported earnings: 24.6. Other multiples: P/B 1.3, P/S 1.4, EV/EBITDA 10.5.
How solid is the balance sheet of Envista Holdings Corp (NVST)?
Balance-sheet figures for Envista Holdings Corp (as of Nov 7, 2026): return on equity 20.5%, debt of 0.47 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is NVST from its 52-week high?
Envista Holdings Corp trades at $25.17, about 17% below its 52-week high of $30.26 and 33% above the low of $18.95 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $6.45 is for.
Which stocks are comparable to Envista Holdings Corp?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Envista Holdings Corp stock attractive at the current price?
The data as of Nov 7, 2026: price $25.17, calculated fair value $6.45 (−74%), Quality Score 69/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NVST calculated?
We run Envista Holdings Corp through 22 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $6.45 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Envista Holdings Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Envista Holdings Corp (NVST)?
The closing price on Nov 6, 2026 was $25.17. Our model-based fair value is $6.45, about 74% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Envista Holdings Corp right now?
The price sits above even our optimistic bull case ($8.06). The favourable scenario is already priced in. Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Envista Holdings Corp
How large is the market capitalisation of Envista Holdings Corp (NVST)?
The market capitalisation of Envista Holdings Corp is $4.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Envista Holdings Corp (NVST)?
The price-to-sales ratio of Envista Holdings Corp is 1.44 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Envista Holdings Corp (NVST)?
Earnings per share at Envista Holdings Corp are $3.88 (price ÷ EPS = P/E 6.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Envista Holdings Corp (NVST)?
The net margin of Envista Holdings Corp is 22.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Envista Holdings Corp (NVST)?
The return on equity (ROE) of Envista Holdings Corp is 20.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Envista Holdings Corp (NVST)?
On an EBIT basis the return on assets of Envista Holdings Corp is −1.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Envista Holdings Corp (NVST)?
The operating margin of Envista Holdings Corp is 11.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Envista Holdings Corp (NVST)?
Revenue at Envista Holdings Corp is growing +3.2% versus a year earlier (3y avg +1.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Envista Holdings Corp (NVST)?
Earnings per share at Envista Holdings Corp are growing +111% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Envista Holdings Corp (NVST) carry?
The net debt of Envista Holdings Corp is $496M (fiscal year 2025, ≈ 2.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Envista Holdings Corp in the live analysis
One click puts Envista Holdings Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 7, 2026